Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Summary

H7N7 is one type of influenza virus that may pose a threat to humans if an outbreak occurs. This study will evaluate the safety and immune response to an H7N7 vaccine in people who have previously received a live attenuated influenza vaccine (LAIV) as part of a research study and people who have not previously received a LAIV.

Timeline

Start

2012-03

Primary completion

2014-03

Completion

2014-03

Publications

• Halliley JL, Khurana S, Krammer F, Fitzgerald T, Coyle EM, Chung KY, Baker SF, Yang H, Martinez-Sobrido L, Treanor JJ, Subbarao K, Golding H, Topham DJ, Sangster MY. High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. J Infect Dis. 2015 Oct 15;212(8):1270-8. doi: 10.1093/infdis/jiv210. Epub 2015 Apr 2.
• Babu TM, Levine M, Fitzgerald T, Luke C, Sangster MY, Jin H, Topham D, Katz J, Treanor J, Subbarao K. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine. 2014 Nov 28;32(50):6798-804. doi: 10.1016/j.vaccine.2014.09.070. Epub 2014 Oct 16.

Drugs

Indications